肌注型HBIg预防肝移植术后乙肝病毒再感染的疗效分析

目的评价小剂量肌肉注射剂型乙肝免疫球蛋白（HBIg）联合核苷类抗病毒药物预防肝移植术后乙肝病毒（HBV）再感染的疗效。方法对2003年9月至2004年12月在中山大学附属第三医院肝移植中心施行肝移植术且符合研究标准的130例病人进行前瞻性研究。采用肌肉注射剂型HBIg联合核苷类抗病毒药物预防术后乙肝病毒再感染，术后监测HBV再感染情况并同国内外研究进行比较。结果130例中128例术后血清HBsAg转为阴性并检测到HBsAb，平均随访12．2个月，HBV再感染率为6.3％（8／128）；对照组再感染率为3．1％，两组比较差异无显著性（P〉0．05）。结论肌注型HBIg联合核苷类抗病毒药物能有效预防肝移植术后HBV再感染。

Efficacy of intramuscular HBIg in preventing hepatitis B virus reinfection after liver transplantation

Objective To evaluate the efficacy of combination of intramuscular HBIg and nucleoside analogs of HBV reinfection.Methods 130 patients underwent liver transplantation and according with the study criterion in our center with HBV related end-stage liver disease during Sep 2003 and Dec 2004 were prospectively studied.All patients received the combination of intramuscular HBIg and oral nucleoside analogs as prophylaxis for HBV reinfection.During the follow-up period HBV markers were tested in due time.The result was compared with domestic and alien studies.Results HBsAg disappeared and HBsAb was detectable in 128 of total 130 patients.The median follow-up was 12.2 months.8 patients (6.3%) developed HBV reinfection.The reinfection in control group was 3.1% (P>0.05).Conclusion Combination of intramuscular HBIg and nucleoside analogs as prophylaxis of HBV reinfection is effective.